Share on LinkedInShare on LinkedIn

ARTICLE · 22 FEBRUARY 2018

Federal Circuit Rules Distribution Agreement May Be Invalidating 'Offer For Sale'

In a February 6, 2018, decision, a Federal Circuit panel reasoned that a pharmaceutical distribution agreement can qualify as an invalidating "offer for sale" ...

United StatesIntellectual Property

In a February 6, 2018, decision, a Federal Circuit panel reasoned that a pharmaceutical distribution agreement can qualify as an invalidating “offer for sale” under 35 USC section 102(b) when the terms of the agreement demonstrate the commercial character and elements of an offer to sell a patented product.

Background

The Medicines Company (Medicines) asserted two patents covering its Angiomax anti-blood-clot drug product (the Product) against Hospira, a generic drugmaker and Abbreviated New Drug Application (ANDA) filer. Medicines developed a new method of formulating Angiomax that reduced impurities. That formulation was the subject of the asserted patents, which were filed on July 27, 2008. Prior to that filing, Medicines, on February 27, 2007, entered into an agreement with Integrated Commercialization Solutions, Inc. (ICS) to distribute the Angiomax formulation. The agreement stated that Medicines “desire[d] to sell the Product” to ICS and that ICS “desire[d]

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from